TAZNI: A phase I/II combination trial of tazemetostat with nivolumab and ipilimumab for children with INI1-negative or SMARCA4-deficient tumors Meeting Abstract
| Authors: | Yi, J. S.; Czaplinski, J.; Bhushan, K.; Forrest, S. J.; Shukla, N.; Mack, S. C.; Hong, A. L.; Kentsis, A.; Stinehart, M.; Ezrre, S.; Strachan, M.; DuBois, S. G.; London, W. B.; Chi, S. N. |
| Abstract Title: | TAZNI: A phase I/II combination trial of tazemetostat with nivolumab and ipilimumab for children with INI1-negative or SMARCA4-deficient tumors |
| Meeting Title: | 2024 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 42 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2024 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2024-06-01 |
| Language: | English |
| ACCESSION: | WOS:001275557406019 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2024.42.16_suppl.TPS10077 |
| Notes: | Meeting Abstract: TPS10077 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
